

## TRADEMARK ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Teva Pharmaceuticals USA, Inc.		05/13/2004	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Teva Pharmaceuticals Curacao N.V.		
Street Address:	Schottegatweg Oost 29D		
City:	Curacao		
State/Country:	NETHERLANDS ANTILLES		
Entity Type:	CORPORATION: NETHERLANDS ANTILLES		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Serial Number:	78179668	BUDEPRION SR	
Serial Number:	78179655	NIFEDIAC CC	
Serial Number:	76140008	NIFEDICAL XL	
CORRESPONDENCE DATA			
Fax Number:	(212)732-3232		
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>			
Phone:	212-732-3200		
Email:	auslander@clm.com		
Correspondent Name:	Rose Auslander Esq.		
Address Line 1:	2 Wall St.		
Address Line 2:	Carter Ledyard & Milburn LLP		
Address Line 4:	New York, NEW YORK 10005		
ATTORNEY DOCKET NUMBER:	TEV01 005		
DOMESTIC REPRESENTATIVE			
Name:			

CH \$90.00 78179668

900129722

TRADEMARK  
REEL: 003955 FRAME: 0517

Address Line 1:

Address Line 2:

Address Line 3:

Address Line 4:

NAME OF SUBMITTER:

DIANE B. MELNICK

Signature:

/diane melnick/

Date:

03/19/2009

Total Attachments: 1

source=Budeprion Nifediac Nifedical assignment#page1.tif

## Trademark Assignment

WHEREAS, Teva Pharmaceuticals USA, Inc., a Delaware corporation, with its principal place of business at 1090 Horsham Road, North Wales, Pennsylvania 19454 USA ("Assignor"), has adopted, owns and is using the following trademarks (the "Marks") in connection with their respective goods, and has applied to register the Marks on the Principal Register of the United States Patent and Trademark Office in the application serial numbers noted below.

Mark	Application Serial No.	Goods
BUDEPRION SR	78/179668	pharmaceutical preparations for the treatment of depression
NIFEDLAC CC	78/179655	pharmaceutical preparations for the treatment of cardiovascular disease; calcium channel blockers
NIFEDICAL XL	76/140008	pharmaceutical preparation for the treatment of cardiovascular diseases

WHEREAS, to the best of Assignor's knowledge no proceeding against said application is pending and no other party makes a claim of ownership to the Mark or the application therefor; and

WHEREAS, Teva Pharmaceuticals Curacao N.V., a corporation of the Netherlands Antilles, with its principal place of business at Schottegatweg, Oost 29D Curacao, Netherlands Antilles ("Assignee"), desires to acquire the Marks and all associated goodwill in said Marks, and the pending application;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, assigns and transfers to Assignee all right, title and interest in and to the Marks, together with the goodwill of the business symbolized by the Marks, and the pending application for registration, and with all claims that could be asserted by Assignor arising out of or relating to the use or ownership of said Marks and application therefor.

ASSIGNOR

Teva Pharmaceuticals USA, Inc.

By: 

Name: Richard S. Egozi, Esq.

Title: Senior Vice President & General Counsel

Dated effective as of: May 13, 2004

1235531.1

0004

TEVA USA LEGAL AFFAIRS

05/13/04 12:06 PM 1235531.1 8813

TRADEMARK

RECORDED: 03/19/2009

REEL: 003955 FRAME: 0519